Cytokinetics, Inc. — 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request metadata identifies 2022 Q4, this filing reports annual results; the provided text does not give separate fourth-quarter financial results.
Business context
Cytokinetics is a clinical-stage biopharmaceutical company developing small-molecule therapies that modulate muscle function. Its lead programs include aficamten for hypertrophic cardiomyopathy (HCM), reldesemtiv for ALS, and omecamtiv mecarbil for heart failure. The company had no commercial product sales in 2022.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Total revenue | $94.6 million | $70.4 million |
| Research and development expense | $240.8 million | $159.9 million |
| General and administrative expense | $178.0 million | $96.8 million |
| Operating loss | $324.2 million | $186.3 million |
| Net loss | $389.0 million | $215.3 million |
| Net loss per share | $4.33 | $2.80 |
| Cash used in operating activities | $299.5 million | $142.5 million |
Revenue included an $87.0 million non-cash recognition related to extinguishment of the Mavacamten royalty obligation; it was not product-sales revenue. The company reported no commercial sales revenue. Operating expenses rose substantially, reflecting clinical development and commercial-readiness spending. Profit margins are not meaningful given the company’s losses and pre-commercial status.
At year-end, cash, cash equivalents and marketable securities totaled $829.3 million, versus $623.8 million a year earlier. Working capital was $710.6 million. Management stated that available resources were expected to fund projected operating requirements for at least 12 months, while noting that estimates depend on assumptions and additional capital may be needed.
Reported borrowings were $609.6 million net carrying value; principal debt was approximately $611.1 million, including $540.0 million of 2027 convertible notes, $21.1 million of 2026 convertible notes and $50.0 million under the Royalty Pharma loan. The company also reported $300.5 million of liabilities related to royalty participation agreements. Total liabilities exceeded assets, resulting in a $107.9 million stockholders’ deficit.
Material changes and developments
- Revenue increased by $24.2 million year over year, largely due to the $87.0 million royalty-related recognition; license revenue fell to zero from $54.9 million.
- R&D expense increased $80.9 million and G&A expense increased $81.2 million. Net loss widened by $173.6 million.
- In July 2022, Cytokinetics issued $540.0 million of 3.50% convertible notes due 2027 and used proceeds plus 8.1 million common shares to repurchase approximately $116.9 million principal amount of 2026 notes. The transaction produced a $22.2 million induced-conversion loss.
- The company entered into Royalty Pharma financing arrangements in January 2022, receiving $50.0 million in loan proceeds and $100.0 million in aficamten royalty-sale proceeds during the year. Further funding is conditional on development milestones.
- Common shares outstanding rose to 94.8 million at year-end from 84.8 million. A March 2023 ATM agreement permits, but does not require, sales of up to $300 million of additional shares.
Outlook, commentary and risks
- Omecamtiv mecarbil: On February 28, 2023, after year-end, FDA issued a Complete Response Letter stating GALACTIC-HF was not sufficiently persuasive and an additional clinical trial was required. The company said it had no plans to conduct that trial and intended to seek a meeting with FDA. The EU application was accepted for review in December 2022, and a China NDA submission was accepted in November 2022.
- Aficamten: SEQUOIA-HCM was enrolling; management expected topline results in Q4 2023. The company expected to begin the MAPLE-HCM Phase 3 trial in the first half of 2023. These are stated expectations, not guarantees.
- Reldesemtiv: The prior Phase 2 FORTITUDE-ALS trial did not meet statistical significance on its primary dose-response endpoint. The COURAGE-ALS Phase 3 trial continued after its first interim analysis; more than 450 of a target of approximately 555 patients had enrolled. A further futility analysis was anticipated in the first half of 2023.
- The filing provides no clear numerical 2023 revenue or net-cash-use guidance in the supplied text. Management expects continued operating losses and cash outflows and anticipates substantial spending on development and potential commercialization.
- Key risks include clinical and regulatory failure or delay, patient enrollment, reliance on contract manufacturers and CROs, uncertain future financing, debt and royalty obligations, competition, reimbursement and pricing pressure, intellectual-property challenges, and potential operational effects from COVID-19.
- Management and the auditor reported effective internal control over financial reporting at year-end; the financial statements received an unqualified audit opinion. The auditor identified estimates of future royalty payments as a critical audit matter because they depend on significant judgment and unobservable assumptions.
Important facts for investors to verify
- Current implications of the FDA’s omecamtiv mecarbil CRL, including any FDA meeting outcome and the status of EU and China reviews.
- SEQUOIA-HCM results, subsequent aficamten milestones, and whether conditional Royalty Pharma funding is available.
- COURAGE-ALS enrollment, interim analyses and trial results, given FORTITUDE-ALS’s missed primary statistical endpoint.
- Cash runway under updated spending assumptions, alongside debt maturities, repayment terms and royalty participation liabilities.
- Potential dilution from convertible notes, equity awards and any ATM share sales.